XML 48 R36.htm IDEA: XBRL DOCUMENT
v3.21.1

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended
--- | --- | ---
Mar. 31, 2021 | Jan. 31, 2021 | May 31, 2020 | Mar. 31, 2020 | Mar. 31, 2021 | Mar. 31, 2020
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 299.3 | $ 52.3
Precision Biosciences, Inc. |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 107.8 |  |  |  |
Merus N.V. |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  | 46.5 |  |  |  |
Asahi Kasei Pharma Corporation |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 20.0 |  |  |  |
Rigel Pharmaceuticals, Inc. |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense | $ 125.0 |  |  |  |  |
Sitryx Therapeutics Limited |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  | $ 52.3 |  |
AbCellera Biologics Inc. |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 25.0 | $ 25.0 |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |